Ralph Kauten is the new CEO of Lucigen, a Middleton company that provides cells, cloning kits and other technology for scientific researchers. The appointment took effect Oct. 20, the company said Wednesday.
Kauten also will continue as CEO of Quintessence Biosciences, a Madison company developing drugs to treat cancer.
At Lucigen, Kauten succeeds David Mead, who founded Lucigen in 1998 and has served as CEO since then. Mead is now chief scientific officer. Kauten's "wealth of leadership experience will be invaluable to the company as we grow and evolve as a premier life science company," Mead said.
Kauten has been a member of Lucigen's board of directors for 10 years, serving as chairman the past four years. He held leadership positions at Promega Corp. and cofounded biotechs PanVera Corp. and Mirus Bio Corp., both of which were acquired by larger companies.